CN110117379A - One kind is for blood perfusion removal LDL adsorbent material and preparation method thereof - Google Patents
One kind is for blood perfusion removal LDL adsorbent material and preparation method thereof Download PDFInfo
- Publication number
- CN110117379A CN110117379A CN201810111001.1A CN201810111001A CN110117379A CN 110117379 A CN110117379 A CN 110117379A CN 201810111001 A CN201810111001 A CN 201810111001A CN 110117379 A CN110117379 A CN 110117379A
- Authority
- CN
- China
- Prior art keywords
- ldl
- resin
- removal
- blood perfusion
- pore
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000008081 blood perfusion Effects 0.000 title claims abstract description 20
- 239000000463 material Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims description 7
- 239000003463 adsorbent Substances 0.000 title abstract description 10
- 239000011347 resin Substances 0.000 claims abstract description 27
- 229920005989 resin Polymers 0.000 claims abstract description 27
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 11
- 239000004584 polyacrylic acid Substances 0.000 claims abstract description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004088 foaming agent Substances 0.000 claims abstract description 10
- 238000001179 sorption measurement Methods 0.000 claims abstract description 8
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims abstract description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 5
- 108010010803 Gelatin Proteins 0.000 claims abstract description 5
- 239000008273 gelatin Substances 0.000 claims abstract description 5
- 229920000159 gelatin Polymers 0.000 claims abstract description 5
- 235000019322 gelatine Nutrition 0.000 claims abstract description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 5
- 235000011187 glycerol Nutrition 0.000 claims abstract description 5
- 229920000669 heparin Polymers 0.000 claims abstract description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical group OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 4
- 210000004369 blood Anatomy 0.000 claims abstract description 4
- 239000008280 blood Substances 0.000 claims abstract description 4
- 229960002897 heparin Drugs 0.000 claims abstract description 4
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 3
- 239000002270 dispersing agent Substances 0.000 claims abstract description 3
- 239000000178 monomer Substances 0.000 claims abstract description 3
- 229920000058 polyacrylate Polymers 0.000 claims abstract description 3
- 239000004342 Benzoyl peroxide Substances 0.000 claims abstract 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims abstract 2
- 235000019400 benzoyl peroxide Nutrition 0.000 claims abstract 2
- 239000003999 initiator Substances 0.000 claims abstract 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical group C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 16
- 239000011806 microball Substances 0.000 claims description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 239000011148 porous material Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000003208 petroleum Substances 0.000 claims description 4
- 150000001336 alkenes Chemical class 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 241000256856 Vespidae Species 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- RKGVNLUAVXQJDL-UHFFFAOYSA-N benzene;prop-2-enoic acid Chemical compound OC(=O)C=C.C1=CC=CC=C1 RKGVNLUAVXQJDL-UHFFFAOYSA-N 0.000 claims description 2
- HRQGCQVOJVTVLU-UHFFFAOYSA-N bis(chloromethyl) ether Chemical compound ClCOCCl HRQGCQVOJVTVLU-UHFFFAOYSA-N 0.000 claims description 2
- 210000001772 blood platelet Anatomy 0.000 claims description 2
- 239000003792 electrolyte Substances 0.000 claims description 2
- -1 polypropylene Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 238000012795 verification Methods 0.000 claims 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960000935 dehydrated alcohol Drugs 0.000 claims 1
- 238000009826 distribution Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 238000003825 pressing Methods 0.000 claims 1
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 9
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 abstract description 3
- 208000020832 chronic kidney disease Diseases 0.000 abstract description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract description 2
- 208000008589 Obesity Diseases 0.000 abstract description 2
- 239000003054 catalyst Substances 0.000 abstract description 2
- 235000012000 cholesterol Nutrition 0.000 abstract description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract description 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 2
- 208000019423 liver disease Diseases 0.000 abstract description 2
- 235000020824 obesity Nutrition 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 2
- 102000004895 Lipoproteins Human genes 0.000 abstract 1
- 108090001030 Lipoproteins Proteins 0.000 abstract 1
- 239000002250 absorbent Substances 0.000 abstract 1
- 230000002745 absorbent Effects 0.000 abstract 1
- 230000000274 adsorptive effect Effects 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 230000010148 water-pollination Effects 0.000 abstract 1
- 238000009835 boiling Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 241001566735 Archon Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- OTPQYXYMKUWQPO-UHFFFAOYSA-N [Na].[K].[P].[Mg].[Ca].[Cl] Chemical compound [Na].[K].[P].[Mg].[Ca].[Cl] OTPQYXYMKUWQPO-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2/00—Processes of polymerisation
- C08F2/44—Polymerisation in the presence of compounding ingredients, e.g. plasticisers, dyestuffs, fillers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/04—Acids; Metal salts or ammonium salts thereof
- C08F220/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
- C08G81/02—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/28—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
- C08J9/286—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum the liquid phase being a solvent for the monomers but not for the resulting macromolecular composition, i.e. macroporous or macroreticular polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2387/00—Characterised by the use of unspecified macromolecular compounds, obtained otherwise than by polymerisation reactions only involving unsaturated carbon-to-carbon bonds
Abstract
It is a kind of highly-safe the present invention relates to synthesizing, validity is ideal, structural behaviour is stablized, the specific good macroporous absorbent resin adsorbent of adsorptive selectivity, it will be filled in blood perfusion device tank body after the adsorbent coating, low-density lipoprotein in blood is removed by blood perfusion (HP) therapy, it is mainly used for treating coronary cardiopathy, lipoprotein is higher, adsorb patient's nephrotic syndrome, chronic renal failure, hepatopathy, diabetes, hyperlipidemia, excessive total cholesterol in low-density caused by obesity or strenuous exercise, triglycerides, low-density lipoprotein etc..The resin adsorption material synthesizes according to the following steps: using acrylic acid and divinylbenzene as monomer, using glycerine as crosslinking agent, using benzoyl peroxide as initiator, using atoleine as pore-foaming agent, using gelatin as dispersing agent, using aluminum trichloride (anhydrous) as catalyst, cross linked polyacrylate divinylbenzene sphere before gel-type is prepared；Then polyacrylic acid divinylbenzene sphere is modified with heparin, to improve the anticoagulant, hydrophily and biocompatibility of resin.
Description
Technical field
The invention belongs to biomedical engineering fields, attached more particularly to a kind of resin for blood perfusion removal LDL
Material and preparation method thereof.
Background technique
According to conservative statistics in 2012, existing more than 200,000,000 hypertensive patients in China, more than 9,000 ten thousand diabetics had 200 every year
Ten thousand people die of cardiovascular and cerebrovascular disease.By the end of the year 2015, China's Patients with Chronic Renal Disease is even more up to 1.3 hundred million person-times.Domestic blood
The product of field of purification is less, especially the higher blood perfusion product of low-density lipoprotein to the ill, even more fewer and fewer；At present
Mainly there are a companies of four, five production blood perfusion devices in the country, year gross sales amount at 1,000,000,000 yuan or so, and as people are to life
The requirement of quality is higher and higher, and this demand can be increasing, therefore the good market prospect of product, once it puts goods on the market, in advance
Meter can bring biggish economic benefit.
With the development of blood perfusion device industry, the purification style of blood perfusion has obtained recognizing for domestic and international medical expert
Together, and with the development of science and technology, some new technologies, new material, new therapy constantly occur, blood perfusion device
Application field, indication also constantly expands.With the development of China's national economy, the raising of medical equipment level, society
Constantly building for medical security system is complete, and hospital more than ground level, which is substantially all, is equipped with dialysis machine, possesses Laminar Airflow Room, has
Province hospital artificial kidney machine equipment rate above county level reaches 70% or more, and in some areas in China, some blood perfusion devices are produced
Product have incorporated the range of medical insurance, these are all that substance important foundation has been established in the development of blood perfusion.
Summary of the invention
This patent is intended to develop the adsorbent in a kind of new type resin adsorption column, is mainly used for treating coronary artery
Property heart disease, nephrotic syndrome, chronic renal failure, hepatopathy, diabetes, hyperlipidemia, obesity or strenuous exercise cause
Low-density lipoprotein it is higher, excessive total cholesterol, triglycerides, the low-density lipoprotein etc. of absorption patient's body.
Technical solution is as follows:
Step 1: acrylic acid, divinylbenzene monomers to be mixed to join to the water of dispersing agent containing gelatin and atoleine pore-foaming agent
In solution, while glycerine crosslinking agent is added, reaction is crosslinked white polypropylene acid phenylethylene micro ball before obtaining；
Step 2: carrying out test tube of hepari to preceding cross linked polyacrylate phenylethylene micro ball using heparin, test tube of hepari acrylic acid benzene second is obtained
Alkene microballoon；
Step 3: polyacrylic acid phenylethylene micro ball is purified and removed pore-foaming agent using petroleum ether, obtain cleaner and not
Final resin containing chloromethyl ether etc..
Summary of the invention of the invention is described in further detail With reference to embodiment.It should be understood that this hair
It is bright that the embodiments are used only to illustrate the invention is not intended to limit the present invention, in the case where not departing from technical thought of the invention, according to
Ordinary skill knowledge and customary means, the various replacements and change made, should all be included within the scope of the invention.
Step 1: the synthesis (lab scale) of polyacrylic acid phenylethylene micro ball:
Reagent list needed for table 1. synthesizes poly- polyacrylic acid phenylethylene micro ball
Concrete operations:
500ml purified water is added in 1000mL three-necked flask (dress blender, return pipe and thermometer), adds the gelatin point of 30g
Powder, is warming up to 45-50 DEG C, and stirring and dissolving forms and stablizes moisture dephasing；By acrylic acid, divinylbenzene, glycerine, peroxidating
Benzoyl, pore cause, atoleine and anhydrous aluminum chloride are thoroughly mixed, and form miscella phase, miscella is added to
It in moisture dephasing, persistently stirs and is warming up to 80 DEG C, carry out polymerization crosslinking and react 4 hours, it is further heated up to 90 DEG C, polymerization is anti-
It answers 4 hours；
After reaction, the Archon of synthesis is filtered, and is cleaned twice with 100 DEG C of boiling water, removal resin surface residual
Gelatin, glycerine etc..
Step 2: the synthesis of test tube of hepari polyacrylic acid phenylethylene micro ball；
Reagent list needed for table 2. synthesizes test tube of hepari polyacrylic acid phenylethylene micro ball
Concrete operations: the acetate buffer solution 500mL that PH is 3.5-4.0 is first prepared, uses anhydrous zinc chloride for catalyst, is gathered
The feed ratio mass ratio of styrene microballoon and heparin sodium is 1:1.5, and the temperature of solution reaction is 60 DEG C, to polyacrylic acid
Phenylethylene micro ball carries out test tube of hepari, the test tube of hepari time about 4 hours, obtains test tube of hepari polyacrylic acid phenylethylene micro ball.
Step 3: the removal of pore-foaming agent and the purifying of resin
Reagent list needed for table 3. closes the removal of pore-foaming agent and the purifying of resin
Concrete operations:
1. drying: by the test tube of hepari polyacrylic acid phenylethylene micro ball of synthesis in forced air drying 2-3 hours at 60 DEG C；
2. the removal of pore-foaming agent: being extracted in the ratio of resin and petroleum ether volume ratio 1:2, renew petroleum ether and carry out continuing to mention
It takes 2-4 times, as far as possible the atoleine in removal microballoon.
3. boiling: adding suitable quantity of water to be heated to boiling in three-necked flask in adsorbent, boiling the retention time is 30 minutes, such as
This repeatedly boiling to pH value to 5.0-7.0 extract: control the residual quantity of liquid wax less than 1%；
4. alcohol extracting: water cooking liquid being replaced into alcohol, electric jacket is heated to alcohol boiling, insulated and stirred about 30 minutes, filters, renew
Alcohol, repeatedly, until adsorbent alcohol washing lotion is in value≤0.03 OD of ultraviolet 200-400nm；
5. redrying: test tube of hepari polyacrylic acid phenylethylene micro ball after boiling, the alcohol extracting vacuum drying 6-8 at 60 DEG C
Hour.
Specific embodiment
Embodiment 1
The Pore Characterization of adsorbent material
The Pore Characterization of more than 4. batches of LDL resins of table
| The resin name of an article | Specific surface area m2/g | Flat diameter bore dia nm | Total pore volume ml/g |
| MR20170601 | 489.4 | 4.214 | 1.147 |
| MR20170620 | 496.3 | 4.265 | 1.165 |
| MR20170714 | 501.4 | 4.367 | 1.028 |
Note: BET pore structure detection method is used.
Embodiment 2
The absorption property of adsorbent material
The absorption property of more than 5. batches of LDL resins of table
| The resin name of an article | Yellow Jackets | VB12 | β2-MG |
| MR20170601 | 99.98% | 92.45% | 85.47% |
| MR20170620 | 100.02% | 91.59% | 86.54% |
| MR20170714 | 99.55% | 92.15% | 84.98% |
Embodiment 3
The security performance of adsorbent material
Being made of the preferable MR20170601 resin progress small lot production and processing tinning of absorption property early period is disposably made
After blood perfusion device, safety animal's whole blood perfusion experimen is carried out；
Adsorption rate of the table 6.MR20170601 resin to each ingredient of blood plasma
| Albumin | Total protein | Blood platelet | Leucocyte | Red blood cell |
| 3.8% | 1.7% | 14.8% | 5.9% | 6.1% |
| 3.8% | 1.8% | 14.5% | 6.1% | 6.2% |
| 3.9% | 1.5% | 14.7% | 5.4% | 6.4% |
The electrolyte adsorption rate of 7. MR20170601 resin pair of table
| Potassium | Calcium | Sodium | Magnesium | Chlorine | Phosphorus |
| 2.8% | 5.4% | -0.2% | 1.7% | 0.9% | 6.7% |
| 2.9% | 5.5% | 0.1% | 1.8% | 0.5% | 6.5% |
| 2.6% | 5.4% | 0.3% | 1.7% | 0.6% | 6.3% |
Claims (6)
1. it is a kind of for blood perfusion removal LDL absorption resin adsorption material, it is characterised in that: its specific surface area be 400~
600m2/ g, pore-size distribution 1-5nm, total pore volume > 1ml/g, resin partial size are about 300~450 μm.
2. a kind of absorption resin adsorption material for blood perfusion removal LDL, absorption property and security performance requirement: 1. pressing
YY0464-2009 standard operation answers >=90% to the adsorption rate of yellow Jackets, VB12；2. by resin/external Plasma volumes than 1/
The adsorption rate of 10 couples of LDL answers >=80%；3. answering >=60% to the absorption of patient LDL when clinical verification；4. in safety animal perfusion
In verification experimental verification, influence of the LDL resin absorbing column to blood formed element should meet: the influence to albumin, total protein answers≤
10%；Influence to blood formed element blood platelet etc. answers≤15%；Influence to each electrolyte answers≤10%.
3. a kind of preparation method of the gel type resin material for blood perfusion removal LDL, it is characterised in that according to the following steps
It carries out:
Step 1: acrylic acid, divinylbenzene monomers to be mixed to join to the water of dispersing agent containing gelatin and atoleine pore-foaming agent
In solution, while glycerine crosslinking agent is added, reaction is crosslinked white polypropylene acid phenylethylene micro ball before obtaining；
Step 2: carrying out test tube of hepari to preceding cross linked polyacrylate phenylethylene micro ball using heparin, test tube of hepari acrylic acid benzene second is obtained
Alkene microballoon；
Step 3: carrying out the removal and alcohol extracting of pore-foaming agent respectively to polyacrylic acid phenylethylene micro ball using petroleum ether and dehydrated alcohol
Purifying obtains final resin cleaner and without chloromethyl ether etc..
4. the preparation method according to claim 3. for the resin material of blood perfusion removal LDL, it is characterised in that
In step 1, the ratio of acrylic acid and divinylbenzene is mass ratio 1:2, and the additional amount of the pore-foaming agent is between styrene-diethyl
The 40-60%wt of alkene benzol mixture.
5. the preparation method according to claim 3. for the resin material of blood perfusion removal LDL, it is characterised in that:
In the step 1, the pore-foaming agent is atoleine, using benzoyl peroxide as initiator.
6. the preparation method according to claim 3. for the resin material of blood perfusion removal LDL, it is characterised in that:
In the step 2, the modifying agent is heparin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810111001.1A CN110117379B (en) | 2018-02-05 | 2018-02-05 | Adsorbing material for removing LDL (low density lipoprotein) in blood perfusion and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810111001.1A CN110117379B (en) | 2018-02-05 | 2018-02-05 | Adsorbing material for removing LDL (low density lipoprotein) in blood perfusion and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110117379A true CN110117379A (en) | 2019-08-13 |
| CN110117379B CN110117379B (en) | 2021-11-12 |
Family
ID=67519167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810111001.1A Active CN110117379B (en) | 2018-02-05 | 2018-02-05 | Adsorbing material for removing LDL (low density lipoprotein) in blood perfusion and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110117379B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114230718A (en) * | 2022-01-27 | 2022-03-25 | 河北利江生物科技有限公司 | Preparation method and application of resin for adsorbing low-density lipoprotein in blood |
| CN114426653A (en) * | 2022-01-26 | 2022-05-03 | 河北利江生物科技有限公司 | For adsorbing beta2Preparation method and application of resin of (E) -MG |
| CN116586048A (en) * | 2023-07-17 | 2023-08-15 | 江苏恰瑞生物科技有限公司 | Modified polystyrene adsorption resin for blood perfusion device and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11332981A (en) * | 1998-05-25 | 1999-12-07 | Tosoh Corp | Method for removing low-density lipoprotein in blood |
| CN104174386A (en) * | 2014-07-28 | 2014-12-03 | 南开大学 | Adsorbent for removing BETA-2 microglobulin in blood |
| CN104492402A (en) * | 2014-12-31 | 2015-04-08 | 珠海健帆生物科技股份有限公司 | Preparation method of adsorbent for adsorbing low-density lipoprotein (LDL) for whole blood perfusion |
-
2018
- 2018-02-05 CN CN201810111001.1A patent/CN110117379B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11332981A (en) * | 1998-05-25 | 1999-12-07 | Tosoh Corp | Method for removing low-density lipoprotein in blood |
| CN104174386A (en) * | 2014-07-28 | 2014-12-03 | 南开大学 | Adsorbent for removing BETA-2 microglobulin in blood |
| CN104492402A (en) * | 2014-12-31 | 2015-04-08 | 珠海健帆生物科技股份有限公司 | Preparation method of adsorbent for adsorbing low-density lipoprotein (LDL) for whole blood perfusion |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114426653A (en) * | 2022-01-26 | 2022-05-03 | 河北利江生物科技有限公司 | For adsorbing beta2Preparation method and application of resin of (E) -MG |
| CN114426653B (en) * | 2022-01-26 | 2023-12-19 | 河北利江生物科技有限公司 | Be used for adsorbing beta 2 Preparation method and application of resin of-MG (polyethylene glycol) |
| CN114230718A (en) * | 2022-01-27 | 2022-03-25 | 河北利江生物科技有限公司 | Preparation method and application of resin for adsorbing low-density lipoprotein in blood |
| CN114230718B (en) * | 2022-01-27 | 2023-11-21 | 河北利江生物科技有限公司 | Preparation method and application of resin for adsorbing low-density lipoprotein in blood |
| CN116586048A (en) * | 2023-07-17 | 2023-08-15 | 江苏恰瑞生物科技有限公司 | Modified polystyrene adsorption resin for blood perfusion device and preparation method thereof |
| CN116586048B (en) * | 2023-07-17 | 2023-09-08 | 江苏恰瑞生物科技有限公司 | Modified polystyrene adsorption resin for blood perfusion device and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110117379B (en) | 2021-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105418946B (en) | The preparation method of secondary cross-linking polymeric adsorbent | |
| CN103483487B (en) | Novel structure product, preparation method and use of styrenic resin | |
| CN110117379A (en) | One kind is for blood perfusion removal LDL adsorbent material and preparation method thereof | |
| CN105561950B (en) | Macroporous absorbent resin and preparation method thereof | |
| CN102049242B (en) | Anion resin for bilirubin absorption and preparation method thereof | |
| US8138289B2 (en) | Imprinted polymeric materials for binding various targets such as viruses | |
| CN105085829B (en) | The preparation method of the macroporous absorbent resin adsorbed for toxic substance | |
| CN105126784B (en) | Adsorbent and preparation method thereof, the adsorbent equipment for blood perfusion | |
| US4140652A (en) | Method of preparing blood-compatible sorbents for recovering exo- and endogenic poisons | |
| CN108031454A (en) | Possesses blood-purifying adsorbing agent of physics specific selectivity and preparation method thereof | |
| CN101224415A (en) | Low density lipoprotein adsorbent for extrinsic blood perfusion and preparing method thereof | |
| CN102212177B (en) | Porous resin with surface hydrophily | |
| JPS59182802A (en) | High molecular weight carbonyl group-containing substance useful as absorbent for nitrogen compound | |
| CN105749886A (en) | Medical polymeric microsphere adsorbent for hemoperfusion apparatus and preparation method of medical polymeric microsphere adsorbent | |
| CN104667897B (en) | For adsorbing high endotoxic phenylethylene resin series in blood | |
| CN105709705A (en) | Molecular imprinting adsorbent for eliminating blood bilirubin and preparation method thereof | |
| CN108191804B (en) | The method of purification of Flavonoid substances Quercetin in a kind of Guava Leaf | |
| CN109513429A (en) | A kind of preparation method of modified adsorbent for bilirubin | |
| CN107200804A (en) | A kind of inflammatory factor macroporous adsorbent and preparation method thereof | |
| Pan et al. | Experimental investigation of a natural favonoid adsorption on macroporous polymers with intrinsic cis-diol moieties recognition function: Static and dynamic methods | |
| CN104587979B (en) | A kind of efficient blood-purifying adsorbing agent and preparation method thereof | |
| CN103224590B (en) | Glabridin molecularly imprinted polymer, as well as preparation method and application thereof | |
| CN111282555B (en) | Macroporous adsorption resin and preparation method thereof | |
| CN105289546B (en) | A kind of preparation method of liquaemin Special adsorbent | |
| CN107513126A (en) | A kind of opaque polymer resin and its application in serum separation gel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A material for removing LDL during blood perfusion and its preparation method Effective date of registration: 20231214 Granted publication date: 20211112 Pledgee: Societe Generale Limited by Share Ltd. Chongqing branch Pledgor: CHONGQING XIERKANG BLOOD PURIFICATION EQUIPMENT RESEARCH DEVELOPMENT CO.,LTD. Registration number: Y2023500000103 |